Eevia receives start order from a new Australian customer for 780 KSEK
Eevia Health Plc (”Eevia” or ”The Company”) has received a sales order for 69 kEUR (780 kSEK) from a new Australian customer for Feno-Sambucus 14, a standardized Elderberry extract.
Eevia received the sales order from an Australian customer through our exclusive distributor in Australia, Ingredient Plus. The end customer is a one of the largest contract manufacturing groups in Australia with sales across Southeast Asia. This is a new customer for Eevia. This first sales order is larger than typical start orders. This customer is known for large volumes, steady business, and reordering. The product is in stock and Eevia will ship immediately. Eevia expects an excellent trajectory with this new customer and significant repeat orders.
Feno-Sambucus™ 14 is an elderberry extract standardized at 14% anthocyanins. Eevia uses a unique purification technology that purifies the product based on chemical class. Contrary to competitors, Eevia’s manufacturing process leaves other critical bioactive compounds than anthocyanins, such as proanthocyanidins (PACs), in the extract. This feature differentiates Eevia's elderberry extract from other elderberry extracts made using membrane filtration technology in the market. These technologies and processing approaches purifies the extract based on molecular size and reduces the presence of large bioactive compounds such as PACs, while Eevia purifies based on affinity of phenolic compounds. This technology retains much more polyphenols in the extract.
CEO Stein Ulve comments: "We are very happy to see our Australian distributor succeed in this product group and pleased to see that our European Elderberry extracts succeed in competition with other less bioactive extracts in the Far Eastern markets."
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.